Séminaire externe

"Structure-based drug design of potent KDM4/5 histone demethylase inhibitors."

Post-translational modifications on Histone tails, including Lysine methylation, are known to play a crucial role in maintaining chromatin architecture and regulating transcription. It's been shown in the past few years that some Histone Lysine Demethylases (KDMs) play an important role in cancer initiation and progression across multiple tumour types.

At the Institute of Cancer Research London, we are involved in a drug-design project targeting KDM4 subfamily members, with the aim to develop potent and cell permeable chemical tools to validate the potential anticancer effects obtained by inhibiting the catalytic activity of these enzymes.

Dr Yann-Vaï LE BIHAN

The Institute of Cancer Research London

Division of Cancer Therapeutics and Division of Structural Biology Hit Discovery and Structural Design team

Londres, Royaume-Uni

Invité par Bertrand Castaing

Vendredi 8 avril 2016 à 11h

Salle de conférence du CBM